A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Rani Therapeutics Holdings, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,500 shares of RANI stock, worth $3,650. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,500
Previous 2,000 25.0%
Holding current value
$3,650
Previous $7,000 28.57%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.06 - $3.99 $25,006 - $48,434
12,139 Added 82.21%
26,904 $58,000
Q2 2024

Aug 14, 2024

BUY
$3.13 - $7.85 $14,814 - $37,154
4,733 Added 47.18%
14,765 $56,000
Q1 2024

May 15, 2024

BUY
$2.98 - $3.8 $29,895 - $38,121
10,032 New
10,032 $31,000
Q2 2023

Aug 14, 2023

SELL
$3.92 - $5.58 $6,330 - $9,011
-1,615 Reduced 15.28%
8,955 $36,000
Q1 2023

May 15, 2023

BUY
$5.07 - $6.89 $53,589 - $72,827
10,570 New
10,570 $54,000

Others Institutions Holding RANI

About Rani Therapeutics Holdings, Inc.


  • Ticker RANI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,492,000
  • Market Cap $35.8M
  • Description
  • Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed P...
More about RANI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.